The Smartest Growth Stocks to Invest $10,000 in As Investors Rotate Out of Tech
When investors take a risk-off attitude, stocks with attractive, growing dividends are often their safe-haven option.
ABT - Abbott Laboratories
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$127.46
DETAILS
HIGH:
$152.00
LOW:
$92.00
MEDIAN:
$125.00
CONSENSUS:
$127.46
UPSIDE:
45.82%
Stock News
3 Stocks to Buy if You Think the Economy Is Heading for a Recession
They have increased their payouts for a combined 171 years straight.
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.
Silver Economy Investing: Why the Healthcare Giants Are in Focus
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
The Dip That Keeps On Dipping: 2 Strong Buy Stocks Near 52-Week Lows With 50%+ Upside Potential
Build-A-Bear Workshop and Abbott Laboratories are compelling dividend stocks, each trading near lows with yields close to 3%. BBW offers a debt-free balance sheet, aggressive share repurchases, and international expansion, positioning for 9.3% earnings CAGR and over 70% upside to its $62 target. ABT, trading at a forward P/E of 15.31x, is undervalued with robust liquidity, ongoing buybacks, and insider buying, despite segment weakness and lowered guidance.
Boston Scientific Bets on Growth Through Strategic M&A Deals
BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?
Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up
ABT shifts to a volume-led Nutrition strategy with pricing moves and new product launches after Q1 sales declined 6%.
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Abbott: Three Supercycles, Mispriced At A 10-Year Low
Abbott Laboratories trades at a decade low of 17.7x forward earnings despite 13.2% Q1 2026 Medical Devices growth and a 54-year dividend streak. Three underappreciated catalysts—Exact Sciences synergy, CMS CGM expansion, and Nutrition margin recovery—could drive $1.27–$1.73 incremental EPS by 2028–2029. Consensus underestimates ABT's commercial leverage, with distribution synergies and CMS reimbursement expansion offering asymmetric upside not priced into current models.
Abbott Laboratories Is On Sale, Don't Overlook It
Abbott Laboratories is trading at a 27% discount to fair value, offering a compelling entry point for long-term investors. ABT's Medical Devices and Diagnostics segments drive robust growth, with the Exact Sciences acquisition adding market-leading oncology diagnostics. Consensus forecasts 9.1% annual EPS growth through 2028, supporting continued 7%-8% dividend growth and a 54-year streak.
Abbott's Medical Device Strategy Supports Long-Term Growth Outlook
ABT's Medical Devices segment posts 8.5% Q1 growth as Electrophysiology, Rhythm Management and Heart Failure deliver strong gains.
Got $5,000? These 3 High-Yielding Stocks Are Trading Near Their 52-Week Lows
These stocks pay more than double the S&P 500 average and have modest valuations relative to the overall market.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Polen Focus Growth Portfolio Q1 2026 Portfolio Update
In Q1 2026, Polen Focus Growth Portfolio returned -17.27% (net of fees) compared to -9.78% for the Index. Starbucks was the top performing absolute and relative contributor in Q1 amid positive signs that CEO Brian Nicol's multi-year turnaround strategy is beginning to bear fruit. In Q1 2026, we initiated new positions in Lam Research, Meta and Rollins, while we sold our holdings in Abbott Laboratories, Adobe, and Boston Scientific, Paycom and Intuit.
This Dividend King's Yield Hasn't Been This High in a Decade. Is It a Buy?
Abbott Laboratories (ABT 1.47%) is offering income investors a rare setup: a yield is approaching 3% while the business continues to grow. The stock isn't a screaming bargain, and rising costs matter, but its record as a Dividend King (increasing its dividends for 50+ consecutive years) makes this healthcare giant worth a closer look.
Wall Street Week Ahead
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
1 Magnificent Dividend Stock Down 30% to Buy and Hold Forever
This company, which has raised its dividend for 54 consecutive years, is on sale.
How to Pick a Healthcare Stock That Can Weather Any Market
Abbott Laboratories is a very diversified company, which can reduce some risks. The medical products maker is a committed dividend payer, too, with a solid yield.
Price Targets
Abbott downgraded to Neutral from Outperform at Daiwa
$92.00
(was $92.75)
Daiwa
Abbott price target lowered to $143 from $144 at Barclays
$143.00
(was $96.83)
Matt Miksic
·
Barclays
Abbott price target lowered to $115 from $132 at Oppenheimer
$115.00
(was $95.46)
UBS
Abbott price target lowered to $115 from $135 at Piper Sandler
$115.00
(was $95.46)
Piper Sandler
Abbott price target lowered to $120 from $145 at Stifel
$120.00
(was $95.46)
Stifel Nicolaus
UBS Reiterates Buy Rating on Abbott Labs (ABT) on DD Medical Device Growth Sustainability
$158.00
(was $108.42)
Danielle Antalffy
·
UBS
Abbott Labs (ABT) Reiterated at Buy by Benchmark After FreeDM Trial Results
$145.00
(was $108.14)
New Street
Abbott price target lowered to $142 from $169 at Barclays
$142.00
(was $109.30)
Barclays
Freedom Capital Markets Upgrades Abbott Labs (ABT) to Buy
$120.00
(was $106.09)
Ilya Zubkov
·
Loop Capital Markets
Abbott price target lowered to $138 from $144 at Evercore ISI
$138.00
(was $108.61)
Evercore ISI
Abbott price target lowered to $132 from $140 at Oppenheimer
$132.00
(was $108.60)
UBS
Abbott price target lowered to $125 from $140 at Mizuho
$125.00
(was $108.60)
Anthony Petrone
·
Mizuho Securities
Abbott price target lowered to $135 from $150 at Piper Sandler
$135.00
(was $108.60)
Piper Sandler
Abbott price target lowered to $125 from $154 at Bernstein
$125.00
(was $108.60)
Bernstein
Abbott price target lowered to $122 from $146 at Wells Fargo
$122.00
(was $108.60)
Larry Biegelsen
·
Wells Fargo
Abbott price target raised to $154 from $150 at Bernstein
$154.00
(was $126.18)
Lee Hambright
·
Bernstein
Abbott price target lowered to $152 from $157 at Goldman Sachs
$152.00
(was $126.18)
Goldman Sachs
Abbott price target raised to $144 from $142 at Evercore ISI
$144.00
(was $123.97)
Evercore ISI
Abbott price target raised to $169 from $162 at Barclays
$169.00
(was $124.19)
Barclays
BTIG Reiterates Buy Rating on Abbott Labs (ABT)
$145.00
(was $126.24)
Marie Thibault
·
BTIG